ALX Oncology Holdings Inc. (ALXO)
Last updated: 2026-10-21 21:28:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
ALX Oncology Holdings Inc. (ALXO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.16, with a market capitalization of $157.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.86 to $2.66. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$157.64M | |
$1.25 | |
$117.45 | |
$0.40 | |
$1.24 | |
847.06K | |
1.17M | |
-- | |
$2.66 | |
$0.86 | |
-- | |
-- |
ALX Oncology Holdings Inc. (ALXO) After-Hours Stock Price
ALX Oncology Holdings Inc. (ALXO) is trading at $1.15 in after-hours trading as of 2026-10-21 21:14:00, down 7.18% ($0.09) from the regular-session close of $1.24.
After-hours trading shows how investors are pricing ALXO after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
ALX Oncology Holdings Inc. (ALXO) 7-Day Stock Price Change
Over the past seven days, ALX Oncology Holdings Inc. (ALXO) moved from $1.26 to $1.16, representing a decline of 8.33% ($0.10).
The stock traded between $0.86 and $1.30 during the period. The latest price is near the upper end of the 7-day range, indicating strong downward.
The average daily volume was 1.78 million shares, up versus the previous seven-day period, indicating higher trading activity.
ALXO 52-Week Price Position
Position in Range: 16.3%
ALXO is currently trading at $1.16, placing it 16.3% of the way from its 52-week low of $0.86 to its 52-week high of $2.66. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is ALX Oncology Holdings Inc. (ALXO)?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
ALX Oncology Holdings Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 48 |
| Exchange | NASDAQ |
| Company Website |
How to Buy ALX Oncology Holdings Inc. (ALXO) Stock on MEXC
Eligible investors can buy real shares of ALX Oncology Holdings Inc. (ALXO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is ALX Oncology Holdings Inc. (ALXO) stock price today?
2.Is ALXO stock going up or down today?
3.What is ALXO pre-market price?
4.What is ALXO after-hours price?
5.Is ALXO stock trading now?
6.Where does ALXO sit relative to its 52-week high and low?
7.What sector is ALX Oncology Holdings Inc. in?
8.What is ALX Oncology Holdings Inc.'s market capitalization and where is it listed?
9.How is ALXO valued in terms of P/E ratio and EPS?
10.Does ALX Oncology Holdings Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ALXO Stock Calculator
Estimate the value between ALXO shares and USD.
ALXO Shares to USD
1.00 ALXO shares = 1.155 USD
Calculations are estimates based on the latest available price and are for reference only.


